منابع مشابه
Anticancer activity of sodium stibogluconate in synergy with IFNs.
Cancer cell resistance limits the efficacy of IFNs. In this study, we show that sodium stibogluconate (SSG) and IFN-alpha synergized to overcome IFN-alpha resistance in various human cancer cell lines in culture and eradicated IFN-alpha-refractory WM9 human melanoma tumors in nude mice with no obvious toxicity. SSG enhanced IFN-alpha-induced Stat1 tyrosine phosphorylation, inactivated intracell...
متن کاملSodium Stibogluconate: Therapeutic use in the Management of Leishmaniasis
Leishmaniasis causes significant morbidity and mortality worldwide. The disease is endemic in developing countries of tropical regions, and in recent years economic globalization and increased travel has also spread to people in developed countries. In the absence of effective vaccines and vector-control measures, the main line of defense against the disease is chemotherapy. Organic pentavalent...
متن کاملA randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
OBJECTIVE To compare the outcome of treatment of Sudanese kala-azar patients treated under field conditions with either branded sodium stibogluconate (SSG) (Pentostam GlaxoWellcome) or generic SSG (Albert David Ltd, Calcutta, supplied by International Dispensary Association, Amsterdam). METHOD Randomised comparison. 271 patients were treated with Pentostam and 245 with generic SSG. RESULTS ...
متن کاملCombination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis.
Sir, Sodium stibogluconate (SSG) is the standard drug used for the treatment of post kala-azar dermal leishmaniasis (PKDL) at a dose of 20 mg/kg/day (maximum 850 mg/day) for at About six patients completed the treatment as one of the patients developed leucopenia while the other was lost to follow up after 56 days. Five of them had an excellent response. The onset of the response was noted as e...
متن کاملComparison of regimens of treatment with sodium stibogluconate in kala-azar.
One hundred and twenty six patients with kala-azar (visceral leishmaniasis) were allocated at random to one of two groups for treatment with sodium stibogluconate. One group was treated for 20 days; in the other group the patients were assessed after 20 days' treatment and treatment was continued if necessary. Both groups were followed up for six months. There was no significant difference in s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2006
ISSN: 1058-4838,1537-6591
DOI: 10.1086/508659